Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema-Reference-Cited by-同舟云学术

Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema

Published:2022-06-13 Issue:8 Volume:52 Page:994-997
ISSN:0954-7894
Container-title:Clinical & Experimental Allergy
language:en
Short-container-title:Clin Experimental Allergy

Author:

Hakl Roman¹²^ORCID,Kuklínek Pavel¹,Sobotková Marta³^ORCID,Krčmová Irena⁴,Králíčková Pavlína⁴^ORCID,Vachová Martina⁵⁶^ORCID,Hanzlíková Jana⁵,Nováčková Martina⁷,Svoboda Michal⁷^ORCID,Kováčová Ingrid⁸^ORCID,Litzman Jiří¹²^ORCID

Affiliation:

1. Department of Clinical Immunology and Allergology St. Anne's University Hospital in Brno Brno Czech Republic

2. Faculty of Medicine Masaryk University Brno Czech Republic

3. Department of Immunology, University Hospital in Motol Charles University Prague Czech Republic

4. Institute of Clinical Immunology and Allergy University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove Hradec Kralove Czech Republic

5. Department of Immunology and Allergology Teaching Hospital Pilsen Czech Republic

6. Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

7. Institute of Biostatistics and Analyses, Ltd. Brno Czech Republic

8. International Clinical Research Centre St Anne's University Hospital Brno Czech Republic

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cea.14182

Reference10 articles.

1. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

2. Clinical Studies of Sudden Upper Airway Obstruction in Patients With Hereditary Angioedema Due to C1 Esterase Inhibitor Deficiency

3. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency

4. The Icatibant Outcome Survey